Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/67495
Title: Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial
Author: Pontes García, Caridad
Gratacós, Jordi
Torres, Ferran
Avendaño, Cristina
Sanz, Jesús
Vallano Ferraz, Antonio
Juanola, Xavier
Miguel, Eugenio de
Sanmartí Sala, Raimon
Calvo Rojas, Gonzalo
Keywords: Malalties de les articulacions
Reumatisme
Espondiloartritis anquilosant
Administració de medicaments
Protocols clínics
Assaigs clínics
Joints diseases
Rheumatism
Ankylosing spondylitis
Administration of drugs
Medical protocols
Clinical trials
Issue Date: 20-Aug-2015
Publisher: BioMed Central
Abstract: Background: dose reduction schedules of tumor necrosis factor antagonists (anti-TNF) as maintenance therapy in patients with spondyloarthritis are used empirically in clinical practice, despite the lack of clinical trials providing evidence for this practice. Methods/Design: to address this issue the Spanish Society of Rheumatology (SER) and Spanish Society of Clinical Pharmacology (SEFC) designed a 3-year multicenter, randomized, open-label, controlled clinical trial (2 years for inclusion and 1 year of follow-up). The study is expected to include 190 patients with axial spondyloarthritis on stable maintenance treatment (≥4 months) with any anti-TNF agent at doses recommended in the summary of product characteristics. Patients will be randomized to either a dose reduction arm or maintenance of the dosing regimen as per the official labelling recommendations. Randomization will be stratified according to the anti-TNF agent received before study inclusion. Patient follow-up, visit schedule, and examinations will be maintained as per normal clinical practice recommendations according to SER guidelines. The study aims to test the hypothesis of noninferiority of the dose reduction strategy compared with standard treatment. The first patients were recruited in July 2012, and study completion is scheduled for the end of April 2015. Discussion: The REDES-TNF study is a pragmatic clinical trial that aims to provide evidence to support a medical decision now made empirically. The study results may help inform clinical decisions relevant to both patients and healthcare decision makers.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/s13063-015-0828-5
It is part of: Trials, 2015, vol. 16, p. 370
Related resource: http://dx.doi.org/10.1186/s13063-015-0828-5
URI: http://hdl.handle.net/2445/67495
ISSN: 1745-6215
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
653994.pdf694.27 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons